Values Lower Than Death Jan J. v. Busschbach, Ph.D. –Erasmus University Rotterdam institute for Medical Technology Assessment (iMTA) PO box 1738 3000 DR.

Slides:



Advertisements
Similar presentations
Measuring outcomes Emma Frew October Measuring outcomes Learning objectives By the end of the session students should be able to – Explain how different.
Advertisements

Emma Frew Introduction to health economics, MSc HEHP, October 2012 Outcomes: part II.
COCOM Kwaliteit van leven in maat en getal Jan van Busschbach.
The impact of Genital Herpes on Health Status Preferences Raj Patel University of Southampton.
A Review and Meta- Analysis of Utility Values for Lung Cancer Julie Migrin ASPH Environmental Health Fellow at the U.S. EPA.
Scaling Session Measurement implies “assigning numbers to objects or events…” Distinguish two levels: we can assign numbers to the response levels for.
1 The Future of Quality of Life Assessment in Cost-Effectiveness Research Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy.
1 The QALYs debate  Prof. dr. Jan J.V. Busschbach, Ph.D.  Erasmus MC  Institute for Medical Psychology and Psychotherapy.
Decision Analysis. What is decision analysis? Based on expected utility theory Based on expected utility theory Used in conditions of uncertainty Used.
1 Does it make a difference for the patient? Survival & Quality of life  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and.
1 A Health Economic View on Borderline Personality Disorder Prof. dr. Jan Busschbach Viersprong Institute for studies on Personality Disorders Medical.
(Cost-)Effectiveness of Psychotherapy for Personality Disorders Jan van Busschbach Prof. Dr. J. van Busschbach Department of Medical Psychology and Psychotherapy.
(Cost-)Effectiveness of Psychotherapy for Personality Disorders Prof. dr. Jan van Busschbach Department of Medical Psychology & Psychotherapy Erasmus MC.
Utility Assessment HINF Medical Methodologies Session 4.
1 Interactive Introduction cost effectiveness Jan J. v. Busschbach, Ph.D. Psychotherapeutic Centrum ‘De Viersprong’, Halsteren
A RECIPE FOR INCOHERENCE: AVERAGING TIME-TRADEOFF OR STANDARD-GAMBLE UTILITIES ACROSS HEALTH ATTRIBUTES Gordon B. Hazen, IEMS Department, Northwestern.
Quality of life Assessment introduction
1 Dyslexia and Cost Effectiveness Prof. dr. Jan van Busschbach De Viersprong Erasmus MC.
Health Economics & Policy 3 rd Edition James W. Henderson Chapter 4 Economic Evaluation in Health Care.
1 EuroQol EQ-5D Jan J. V. Busschbach, Ph.D Psychotherapeutic Centrum ‘De Viersprong’, Halsteren Department of Medical.
Measuring and valuing health outcome Montarat Thavorncharoensap, Ph.D. 1: Faculty of Pharmacy, Mahidol University 2. HITAP, Thailand.
This paper is the logical continuation of my earlier article: Shock Therapy versus Gradualism: The End of the Debate (Explaining the Magnitude of the Transformational.
1 EQ-5D, HUI and SF-36 Of the shelf instruments…..
1 Health Economics  Comparing different allocations  Should we spent our money on Wheel chairs Screening for cancer  Comparing costs  Comparing outcome.
Overview of the EQ-5D Purpose and origins of the descriptive system.
Decision Analysis. Real Case 63 year old housewife with 6 grown children. 10 year history of stable angina pectoris. 8 years ago she had total hip replacement.
How can societal concerns for fairness be integrated in economic evaluations of health programs? Erik Nord, PhD, Senior Researcher, Norwegian Institute.
Measuring Health Outcomes
Why use the EQ-5D? What are the alternatives?. What are the alternatives for Direct valuation? Other VAS Time Trade-Off Standard Gamble Willingness to.
University of Minnesota Medical Technology Evaluation and Market Research Department of Healthcare Management Course: MILI/PUBH 6589 Spring Semester, 2013.
Economic evaluation Definition - the comparative analysis of alternative courses of action in terms of both their cost and consequences.
Quality of Life in People with and at Risk for Type 2 Diabetes: Findings from the Study to Help Improve Early Evaluation and Management of Risk Factors.
1 Reconciliation of Economic Arguments and Clinical Practice Monday November 4, 2002 ISPOR, Rotterdam Jan Busschbach PhD, –Department of Medical Psychology.
Economic evaluation of drugs for rare diseases CENTRE FOR HEALTH ECONOMICS K Claxton, C McCabe, A Tsuchiya Centre for Health Economics and Department of.
Outcomes in Decision Analysis: Utilities, QALYs & DALYs, and Discounting DCEA 24 January 2013 James G. Kahn.
1 QALY, Burden of Disease and Budget Impact  Jan J.V. Busschbach, Ph.D.  Erasmus MC, Rotterdam, The Netherlands  
1 The valuation of disease-specific health states to facilitate economic evaluation E. Kok, E. Stolk, Jan J. v. Busschbach Address: –Jan v. Busschbach.
Interactive Introduction cost effectiveness Jan J. v. Busschbach, Ph.D Viersprong Institute for studies on Personality Disorders (VISPD)
1 Cost effectiveness as argument for reimbursement in prevention Jan J. v. Busschbach, Ph.D. Erasmus MC –Institute for Medical Psychology and Psychotherapy.
1 Interactive introduction in Quality of life Assessment Jan J. v. Busschbach, Ph.D. Department of Medical Psychology and Psychotherapy, Erasmus MC
1 EQ-5D, HUI and SF-36 Of the shelf instruments…..
Survey of alternative uses of ACTIVE data, review of completed work and lessons learned Friday Harbor Advanced Psychometrics Workshop June 9-13, 2014 Presenter:
Overview of Health-Related Quality of Life Measures May 22, 2014 (1:00 – 2:00 PDT) Kaiser Methods Webinar Series 1 Ron D.Hays, Ph.D.
Quality of life and Cost-Effectiveness An Interactive Introduction Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy Viersprong.
1 Scale recalibration effects in dementia patients and their proxies Sander Arons Dept. of Epidemiology, Biostatistics and HTA Radboud University Nijmegen.
Cost-Effectiveness of Psychotherapy for Personality Disorders Soeteman, Busschbach, Verheul.
Cost-effectiveness in the quest to convince the outside world Dr. Jan Busschbach De Viersprong Erasmus MC
1 Health outcome valuation study in Thailand Sirinart Tongsiri Research degree student Health Services Research Unit, Public Health & Policy Department.
1 Interactive Introduction Cost Effectiveness and Psychotherapy Jan J. v. Busschbach, Ph.D. Psychotherapeutic Centrum ‘De Viersprong’, Halsteren
1 The Economics of Health Care and New Technologies Friday October 18, 2002 Between Technology and Humanity, Brussels Jan Busschbach PhD, –Department of.
Measuring Family HRQOL Spillover Effects Using QALYs Lisa A. Prosser, PhD University of Michigan CANS Special Topics Conference October 14, 2015.
Hermann P. G. Schneider, Alastair H. MacLennan and David Feeny
1 Value of Information in relation to risk management  Prof. Dr. Jan J.V. Busschbach.
“Introduction to Patient Preference Methods used for QALYs” Presented by: Jan Busschbach, PhD, Chair Section Medical Psychology and Psychotherapy, Department.
Thirty down, only ten to go?! Awareness and influence of a 10-year time frame in TTO Floor van Nooten, Xander Koolman, Werner Brouwer 1 A paper introduced.
Cost-Effectiveness of Psychotherapy (for Personality Disorders) Prof. dr. Jan van Busschbach.
How to weight cost effectiveness in appraisal NVTAG / CVZ course: The appraisal process, work in progress 22th of April 2009 Jan van Busschbach.
(Cost-)Effectiveness of Psychotherapy for Personality Disorders Jan van Busschbach Prof. Dr. J. van Busschbach Department of Medical Psychology and Psychotherapy.
Effect of framing of death on health state values obtained from DCEs Dr. Esther W. de Bekker-Grob by Jonker, de.
1 Quality of life and Cost-Effectiveness An Interactive Introduction Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy.
1 Are values cultural determined…..  Many believe that QoL is cultural determined  One of the starting points of the EuroQol group.
1 Cost-Effectiveness in Medicine An Interactive Introduction  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and Psychotherapy.
1 VAS, SG, TTO and PTO An Interactive Introduction.
Preference Assessment 1 Measuring Utilities Directly
Benefits of Exercise over Lifespan Going for the 3 Increases: Increase in Health, Increase in Happiness & Increase in Energy Strategies for Success in.
How Patients Discuss Their Risk: Words and Numbers
The Relationship Between Mental and Physical Health
Outcomes: part II Emma Frew
Clinical palliative care for surgeons: part 1
Measuring outcomes Emma Frew October 2012.
Presentation transcript:

Values Lower Than Death Jan J. v. Busschbach, Ph.D. –Erasmus University Rotterdam institute for Medical Technology Assessment (iMTA) PO box DR Rotterdam (secretariat) (fax)

Values below the value of death are associated with: In patients with extreme bad health states –Chronic: cancer, pain –Temporary: invasive therapy In patient with extreme high or low arousal –Psychological distress; coma; waiting room, confined to bed Euthanasia

Economic evaluation Acknowledge values lower than death Values lower than death –Heath Utility Index (HUI) Torrance GW. Measurement of health state utilities for economic appraisal. Journal of Health Economics 1986; 5: –EuroQol Brooks R, with the EuroQol Group. EuroQol: the current state of play. Health Policy 1996; 37: –The Rosser & Kind Index Williams A. For Debate... Economics of Coronary Artery Bypass Grafting. British Medical Journal 291: , No values below death –The Quality of Well-being Scale (QWB) Read J., Quinn R., Hoefer M. Measuring overall health: an evaluation of three important approaches. Journal of Chronical Diseases, Vol 40, suppl. 1, pp. 7S-21S, 1987.

Clinical decision making Rarely confronted with values below death because: Patient is already dead –Can not survive a bad health state for long –Euthanasia Patients value their own health states higher –Coping (Medical terminology) –Preference drift (Economical terminology) –Cognitive dissonance reduction (Psychological terminology) Patients are often "Lexicographic" –In a trade-off between quality of life and time, lexicographic patients always chose maximum survival. –They are lexicographic until “Maximum Endurable Time”

Visual Analog scale If death is not the bottom anchor, values below the value of death are possible. V(X) = (X - V(D)) / (V(H) - V(D)) –X is the scale placement –V(X) is the value of X –V(D) is the value of death (often zero) –V(H) is the value of healthy Note: values above “healthy” are also possible: –“Best health state” as top anchor Healthy Death X Healthy Death X Worst health state

Standard Gamble State X Healthy Death P 1-P Below the value of death Healthy Death P 1-P Above the value of death State X Torrance, 1986 Square = choice Circle = chance Above death V(X) = p Below death V(X) = – p / (1 – p)

Time Trade-Off Torrance, 1986 Healthy 1. 0 State X V(X) Healthy 0.0 Time X t Healthy 1. 0 State X V(X) Healthy 0.0 Time X t Above death: V(X) = X / t Below death: V(X) = X / (X – t)

Alternative Time Trade-Off MVH study (York) Healthy 1. 0 State X V(X) Healthy 0.0Time X’ t Below death: V(X’) = (X’ – t) / X’ First choice between above or below dead Time trade-off above death is classic Below death, healthy life is promised after bad state

The problems below death Complicated No lower limit Outliers dominate mean values What can we do….. –Cut-off at zero, – 1, any negative number? –No documented transformation function –If we transform negative values, above and below death become incoparable –Median instead of mean

Can we use negative values? Bizarre political interpretation –In health economics, »Death would implicate additional quality of life »Death would implicate additional QALY’s Bizarre clinical advise –If you die, your life improves…...

Torrance and the rise a fall of values below death 1970 –Does not mention the problem explicitly –Uses good and mild health states 1982 –Introduces negative values –In 3 articles he advises a limit at -1 »Linear transformation (data remains skewed) –No justification 1986 –Limit at -1 –Further work on values below death would be “underway” (reference: Berlin 1984)

Torrance and the rise a fall of values below death 1992 –No more negative values: cut-off at zero –Negative values have no lower limit which “caused some concern” and “requires ad hoc adjustments” –“Negative values may be qualitatively different from positive values” 1996 –Uses “… the current default approach, which is to set negative utility scores worse than death to zero.” –Speaks about “… an upwards bias…” –“…Unfortunately, methodological issues for states worse than death have not as yet been resolved”.

The York Group The MVH-study –N = 3000, general public, 45 EuroQol Health states valued with »(non standard) EuroQol VAS »time trade-off Range from –1.0 to 1.0 –Formula: x/ (x is number of years in full heath) –Transformtion is not linear: also removes skewness VAS – 4 out f 243 health states were negative Time trade-off – 82 out of 243 were negative

The York Group Has a strong opinion that –negative values exits –are useful Arguments for transformation to -1 are –Extreme negative values would have a great impact –Has been done before (Patrick, et al, 1994) »Patrick: “Not longer utilities…. »Torrance: “Not longer utilities, not even for only use below death ––1.0 is mirror vision of + 1.0

Conclusions Psychometric problems –Negative values have no lower limit –Outliers dominate mean values –There is no elegant transformation function Negative values have a difficult interpretation Health states with negative values are –rare –temporary

Negative states There are indeed health states with a negative value –People are prepared to give in life to avoid health state